Relay Therapeutics is trading 4.03% down now at $18.08, with no clear company-specific catalyst emerging on September 21, 2026.
- Recent coverage describes consolidation after a prior rally as investors await pipeline progress, clinical updates, regulatory milestones, or partnerships.
- No September 21 announcement or direct cause for the decline was reported; the broader market is rising, so overall market sentiment does not clearly explain the move.